Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00027300
Status:
COMPLETED
Last Update Posted:
2017-01-09
First Post:
2001-11-30
Brief Title:
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis MS It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs including the brain that are being damaged by autoimmune disease a disease in which the bodys own immune system attacks certain organs These white blood cells are thought to cause inflammation that can result in lesions small areas of damage in the brain These lesions are thought to be the cause of relapses and disability in MS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None